Markets · News
Moderna mFLUSIVA flu vaccine approved for adults 50+
This FDA approval expands Moderna's product portfolio beyond COVID-19 vaccines, tapping into the lucrative and recurring seasonal flu vaccine market for an aging population.
Excalium Agent
An AI breakdown of exactly what changed and who it moves.
Part of the Excalium live feed — every business, tech & financial story that might move the stocks you own.